估算加拿大安大略省复发性滤泡性淋巴瘤和边缘区淋巴瘤的疾病负担。

Estimating the Burden of Illness of Relapsed Follicular Lymphoma and Marginal Zone Lymphoma in Ontario, Canada.

机构信息

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON M5G 2C1, Canada.

Department of Medicine, University of Toronto, Toronto, ON M5S 3H7, Canada.

出版信息

Curr Oncol. 2023 Apr 30;30(5):4663-4676. doi: 10.3390/curroncol30050352.

DOI:10.3390/curroncol30050352

PMID:37232810

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10216939/

Abstract

BACKGROUND

Many patients with advanced follicular lymphoma (FL) and marginal zone lymphoma (MZL) relapse after first-line chemotherapy.

OBJECTIVE

To examine healthcare resource utilization (HCRU) and cost, treatment patterns, progression, and survival of patients with FL and MZL who relapse after first-line treatment, in Ontario, Canada.

METHODS

A retrospective, administrative data study identified patients with relapsed FL and MZL (1 January 2005-31 December 2018). Patients were followed for up to three years post relapse to assess HCRU, healthcare costs, time to next treatment (TTNT), and overall survival (OS), stratified by first- and second-line treatment.

RESULTS

The study identified 285 FL and 68 MZL cases who relapsed after first-line treatment. Average duration of first-line treatment was 12.4 and 13.4 months for FL and MZL patients, respectively. Drug (35.9%) and cancer clinic costs (28.1%) were major contributors to higher costs in year 1. Three-year OS was 83.9% after FL and 74.2% after MZL relapse. No statistically significant differences were observed in TTNT and OS between patients with FL who received R-CHOP/R-CVP/BR in the first line only versus both the first- and second- line. A total of 31% of FL and 34% of MZL patients progressed to third-line treatment within three years of initial relapse.

CONCLUSION

Relapsing and remitting nature of FL and MZL in a subset of patients results in substantial burden to patients and the healthcare system.

摘要

背景

许多患有晚期滤泡性淋巴瘤（FL）和边缘区淋巴瘤（MZL）的患者在一线化疗后复发。

目的

在加拿大安大略省，研究接受一线治疗后复发的 FL 和 MZL 患者的医疗资源利用（HCRU）和成本、治疗模式、进展和生存情况。

方法

一项回顾性的行政数据研究确定了复发的 FL 和 MZL 患者（2005 年 1 月 1 日至 2018 年 12 月 31 日）。对患者进行了长达三年的随访，以评估 HCRU、医疗保健成本、下一次治疗的时间（TTNT）和总生存（OS），并按一线和二线治疗进行分层。

结果

该研究确定了 285 例 FL 和 68 例 MZL 患者在一线治疗后复发。FL 和 MZL 患者的一线治疗平均持续时间分别为 12.4 个月和 13.4 个月。药物（35.9%）和癌症诊所费用（28.1%）是导致第一年费用较高的主要原因。FL 复发后的三年 OS 为 83.9%，MZL 复发后的三年 OS 为 74.2%。在仅接受一线 R-CHOP/R-CVP/BR 治疗的 FL 患者与一线和二线均接受治疗的患者之间，TTNT 和 OS 没有统计学上的显著差异。FL 患者中有 31%，MZL 患者中有 34%在初始复发后的三年内进展到三线治疗。